Simicol

Quick links to important sections

Simicol

Selected form

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Simicol

Simicol Quick Facts

Property Description
Active ingredient Simethicone (Simeticone [INN])
Form Oral liquid, drops, tablets, or capsules
Pharmacological class Antiflatulent / Gastrointestinal Agent
Common use Physical relief of gas, bloating, and pressure
Origin Synthetic Silicone Compound

Simicol Defined: An Over-the-Counter Antiflatulent

Simicol is a widely distributed commercial brand name for a non-prescription (OTC) medication, primarily classified as an antiflatulent. Its single active ingredient is Simethicone, internationally recognized as Simeticone by the International Nonproprietary Name (INN). This compound belongs to the gastrointestinal agent class and is designed to manage the physical symptoms of excess gas. Simethicone is classified as an effective antiflatulent that physically manages intestinal gas.

A key differentiating feature of the Simicol brand is its positioning toward easily administered liquid forms, such as oral drops and suspension, making it a prominent option for the pediatric patient group, although adult forms are also available. The drug is inert and exhibits non-systemic absorption, limiting its therapeutic effect strictly to the digestive tract.

Composition, Forms, and General Relief

The composition of Simicol relies on its active component, Simethicone, a synthetic silicone compound. Chemically, it is an activated mixture of long-chain Polydimethylsiloxane and Silicon dioxide (silica gel). Simicol is administered via the oral route and is available in multiple dosage forms, including the aforementioned oral drops, suspension, chewable tablets, and swallowable capsules.

The general purpose of this medication is to provide physical relief from discomfort. Simethicone functions as an anti-foaming agent by reducing the surface tension of trapped gas bubbles. This action causes small bubbles to rapidly coalesce (merge) into larger pockets of gas, enabling facilitated gas elimination. This mechanism helps alleviate the subjective sensations of pressure and fullness that arise from accumulated gastrointestinal gas.

Regulatory References

  1. Simethicone - StatPearls - NCBI Bookshelf

What side effects are possible with Simicol?

Possible Side Effects and Safety Information

The safety profile of Simicol (Simethicone) is determined by its classification as a non-systemically absorbed antiflatulent, meaning the active substance is not absorbed into the bloodstream. Adverse reactions are primarily localized and officially documented according to regulatory System-Organ Classes (SOCs).


Adverse Reaction Classifications

Official regulatory documents generally classify adverse events with a Frequency Not Known (meaning the frequency cannot be estimated from available data) or as Uncommon.

System-Organ Class Officially Documented Effects
Gastrointestinal Disorders Nausea, constipation, diarrhea, vomiting
Immune System Disorders Hypersensitivity reactions (e.g., rash, pruritus, swelling)

Serious Safety Considerations

The most serious safety concerns relate to rare but potential severe hypersensitivity reactions (Immune System Disorders). These are officially documented to include manifestations such as Anaphylaxis and Angioedema (serious swelling of the face or throat).

Safety Restrictions and Limitations

Simicol's official regulatory labeling includes critical contraindications that apply to all administration forms:

  • Known Hypersensitivity to the active ingredient or excipients.
  • Gastrointestinal Perforation or Known or suspected intestinal obstruction.

Population Considerations

The medicine is authorized for use in pediatrics, including infants. Due to the lack of systemic absorption, the risk profile for other populations, such as older adults, is generally considered comparable to that of younger adults, and the substance is not expected to be excreted in breast milk.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory profile for Simicol (Simethicone) overexposure is structured by its pharmacological classification as a chemically inert and non-systemically absorbed agent. This means the compound is not absorbed into the bloodstream and acts exclusively within the digestive tract. As documented by official health authorities, acute systemic toxicity is not expected following ingestion of large quantities. No systemic, life-threatening outcomes are recorded in official labeling.

Overdose Risk & Manifestation Official Regulatory Statement
Systemic Toxicity Not expected due to the drug's non-absorbed nature and inert properties.
Antidote Availability No specific antidote is known.
Potential Symptoms Constipation is the only theoretical gastrointestinal manifestation documented in some official labels.

In the event of accidental overexposure, the standard regulatory guidance is to seek medical assistance or contact a Poison Control Center right away. The official management procedure is solely symptomatic and supportive. This approach includes procedures like providing fluids and observation to manage any potential symptoms, such as the theoretical occurrence of constipation. Due to the favorable profile, official labeling states that Simethicone products are exempt from the mandatory general warning statement required for systemically active medications, and no population-specific considerations are documented regarding toxicity.

Therapeutic Uses of Simicol

Main Uses and Indications

Simicol is primarily used for the relief of symptoms associated with the accumulation of excess gas in the digestive tract. It is frequently employed to manage discomfort in infants and young children, though it is also used in adults for similar gastrointestinal concerns.

Infantile Colic

In infants, the buildup of gas in the stomach and intestines can lead to a condition often referred to as colic. This is characterized by periods of intense crying, fussiness, and apparent abdominal discomfort. Simicol is used to assist in the expulsion of these gas bubbles, which may help reduce the physical pressure causing the distress.

Flatulence and Abdominal Bloating

The medication is used to treat generalized abdominal bloating and flatulence. These conditions occur when gas becomes trapped in the digestive system, leading to a sensation of fullness, tightness, or visible swelling of the abdomen.

Diagnostic Preparation

Simicol may be utilized as an adjunct in preparation for certain medical diagnostic procedures, such as gastroscopy or abdominal ultrasounds. In these contexts, it helps to eliminate gas shadows and foam that could interfere with the clarity of the imaging or the visual examination of the gastrointestinal lining.

Benefits and Mechanism of Action

Reduction of Surface Tension

The primary benefit of Simicol is its ability to change the surface tension of gas bubbles within the stomach and intestines. By lowering this tension, small, trapped bubbles are encouraged to coalesce into larger bubbles.

Ease of Gas Elimination

Once the gas bubbles have combined into a larger volume, they are more easily passed through the digestive system. This allows the body to eliminate the gas more efficiently through natural processes, such as burping or passing flatus, thereby relieving the internal pressure and associated discomfort.

Non-Systemic Action

A significant characteristic of the active ingredient in Simicol is that it acts locally within the gastrointestinal tract. It is not absorbed into the bloodstream, meaning its effects are confined to the physical breakdown of gas bubbles rather than interacting with the body's systemic biological processes.

Regulatory References

  1. NIH StatPearls overview of Simethicone

Eligibility and Restrictions for Use

Official Population Eligibility for Simicol (Simethicone)

The use of Simicol is determined by its classification as a non-systemically absorbed medicine, leading to minimal restrictions primarily based on allergy and acute mechanical conditions. All eligibility information is strictly based on governmental regulatory documents.

Contraindicated Populations

Simicol must not be used (is formally contraindicated) in specific groups according to regulatory labeling:

  • Patients with known hypersensitivity or allergy to simethicone or any other component in the product.
  • Patients with suspected or confirmed Gastrointestinal (GI) Obstruction or Intestinal Perforation.

Age-Related and Special Population Status

Population Group Eligibility Status (Regulatory Labeling)
Adults and Older Children Permitted for use under standard conditions.
Infants (Under 2 Years) Conditional use. Requires the advice and supervision of a doctor per national regulatory guidance.
Pregnant Women Permitted for use; no effect is anticipated due to negligible systemic absorption.
Lactating Women Permitted for use; the compound does not pass into breast milk.
Renal/Hepatic Impairment No specific restriction documented, as the medication is not systemically absorbed or metabolized.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile of Simicol (Simethicone) is exceptionally limited due to its physiological inertness and non-systemic absorption. The compound remains exclusively within the gastrointestinal tract and is not taken up into the bloodstream, establishing a distinct regulatory profile.

Official Interaction Profile

Category Regulatory Statement
Systemic Metabolic Interactions None documented. Simethicone does not participate in systemic metabolic pathways, such as those involving CYP450 enzymes or drug transporters (e.g., P-gp), and therefore lacks documented systemic pharmacokinetic interactions.
Pharmacodynamic Interactions None documented. Official labeling reports no additive or synergistic effects with other agents.
Food, Alcohol, Supplements No known interactions with food or alcohol are reported in primary regulatory labeling.

Documented Exposure-Altering Interaction

The only class of drug interaction documented by regulatory authorities involves physical interference with gastrointestinal absorption. Simicol may reduce the systemic absorption of orally administered thyroid replacement hormones (e.g., Levothyroxine). This is a pharmacokinetic outcome resulting in a potential decrease in the co-administered drug's plasma concentration.

Mandatory Administration Rule

To mitigate the risk of reduced exposure, official prescribing information mandates a timing separation rule. Simicol must be administered at least 4 hours before or after the dose of any thyroid replacement medication.

Mechanism of Action

Physicochemical De-foaming Action

Simethicone operates through a non-pharmacological mechanism that is entirely local and physicochemical. As a surfactant, the agent directly targets the surface tension of the air/liquid interface of the foam trapped in the digestive tract. By lowering this surface tension, the compound causes the unstable liquid films of the small gas bubbles to rupture and break down. This mechanism defines the action of the agent, as it acts purely on the physical state of the gas rather than affecting any biological pathways or systems.

Facilitation of Gas Elimination

The physical breakdown of the foam initiates a rapid mechanistic cascade where numerous small, stable bubbles are forced to coalesce (merge) into fewer, larger pockets of gas. Since Simethicone is not systemically absorbed, this effect is confined solely to the gut lumen. The resulting larger gas volumes are then subject to accelerated propulsion by the body's natural motility (peristalsis). The facilitated state of the gas supports the physiological process of clearance via eructation or flatulence, resulting in adjustments in intraluminal gas volume.

Dosage and Administration Information

Administration Guidelines

Simicol (Simethicone) is administered exclusively through the oral route for its intended non-systemic action within the digestive tract. The administration schedule is typically as needed (PRN) for symptomatic relief, with doses generally taken after meals and at bedtime for optimal effect. Standard protocols establish precise dosing rules based on age and formulation.

Population Single Dose Range Maximum Daily Limit (24 hrs)
Adults 40 mg to 250 mg 500 mg
Children (2–12 years) 40 mg 480 mg
Infants (Under 2 years) 20 mg 240 mg

Usage is constrained by these established daily maximums; exceeding the limit for any population requires the advice and supervision of a physician. The medication is designed for short-term, episodic use for symptomatic gas relief.

Specific preparation and intake procedures must be followed depending on the dosage form. Oral suspensions or drops must be shaken well immediately prior to use, and the dose must be accurately measured with a calibrated dropper or syringe. Chewable tablets must be chewed thoroughly before swallowing for proper administration. If symptoms persist or recur after a short course of use (typically 10 to 14 days), consultation with a healthcare professional is advised. This procedural structure ensures standardized administration according to established guidelines.

Recent Clinical Evidence

Research evidence / Overview of studies for Simicol

Evidence for Symptomatic Relief of Gas and Bloating

This section summarizes the type of research that has been used in exploring symptomatic changes related to physical discomfort, pressure, and fullness attributed to trapped gastrointestinal gas. Researchers have conducted short-term randomized controlled trials (RCTs) and systematic reviews applied in studies examining patient-reported experiences. These studies typically monitored outcomes related to physical discomfort over short observation periods, often lasting a few days up to one week.

Studies monitored how symptoms evolved in the observed populations, focusing on patient-reported outcomes describing perceived discomfort. The consistency of these findings remains an area of uncertainty. The evidence highlights what is known but also what is still uncertain regarding reliable short-term symptomatic change, as many trials reported a noticeable change in the placebo control groups. The long-term effects are not fully established, as follow-up durations were limited.

Research on Pre-Procedure Use in Diagnostic Imaging

Simicol was evaluated in acute clinical trials that studied its application in diagnostic procedures prior to certain examinations, such as endoscopy. These studies are relevant in evidence describing how visual quality is measured on an objective scale, focusing not on patient feeling, but on the clarity of the resulting image.

Studies explored outcomes related to image quality. Findings consistently describe patterns indicating measured changes in gas bubbles and changes in the clarity of the viewing field as judged by the clinicians conducting the procedure. The research scope is limited because it focuses exclusively on a technical endpoint (image clarity) and not on symptomatic relief. Research provides context but not individual predictions concerning symptomatic response.

Studies in Special Populations: Focus on Infants and Children

The research landscape includes trials and studies that evaluated Simicol in special populations, particularly infants. Simicol was evaluated in RCTs relevant in trials assessing short-term or episodic symptom patterns in infants experiencing fussiness or excessive crying often attributed to gas (infant colic). Studies report how symptoms evolved in the observed populations, but findings were mixed in pediatric groups. Evidence suggests that for infant colic, some trials noted similar measured changes in symptoms when comparing the Simicol group to the control group, indicating that certainty remains low regarding consistent findings in this population.

Frequently Asked Questions (FAQ)

Common questions about Simicol (FAQ)


Q: Is Simicol the same type of medicine as [similar drug name]?

A: Simicol contains the active ingredient simethicone, which is classified as an antiflatulent medicine. According to regulatory documents, other drug products that contain simethicone are considered the same type of medicine, as they share the same physical mechanism of action.


Q: How long does it usually take for Simicol to start working?

A: Simicol is a physical agent that works locally in the digestive tract by breaking down trapped gas bubbles. This mechanism can result in rapid relief once the medicine is fully dispersed within the gut. For forms like chewable tablets, the official directions specify that chewing thoroughly aids in the medicine’s dispersion within the gut.


Q: What should I do if I think I missed a dose of Simicol?

A: Simicol is a medicine that is typically taken only as needed (PRN) for symptomatic relief of gas and bloating. Because it is used only when symptoms occur, there is usually no need to make up for a missed dose if relief is not currently required.


Q: Is it normal to feel a certain way when first taking Simicol?

A: The active ingredient in Simicol, simethicone, is generally well tolerated because it is not absorbed into the bloodstream. Official regulatory documentation reports only rare occurrences of mild and local gastrointestinal disturbances, such as nausea or diarrhea.


Q: What happens if you stop taking Simicol suddenly?

A: Because Simicol works only locally within the digestive tract and is not absorbed into the bloodstream, stopping the medication suddenly is not associated with withdrawal or rebound effects.


Q: Does Simicol cause weight gain?

A: Simicol is not absorbed into the body's systems; it works only in the stomach and intestines. Due to this non-systemic mechanism, side effects that involve whole-body systems, such as weight gain, are not expected and are not reported in official regulatory documents.


Q: What are the most commonly reported side effects of Simicol?

A: Regulatory documents classify the frequency of adverse effects for Simicol as either uncommon or 'frequency not known,' which means the precise rate cannot be determined from available data. Therefore, there are no specific, quantified side effects that can be officially designated as the 'most common' to report.


Q: What is the difference between Simicol and a supplement for the same condition?

A: Simicol is classified as an Over-the-Counter (OTC) Drug under a federal regulatory monograph. This status means the medication and its manufacturing are governed by specific federal standards for drug quality, labeling, and purity, which differ from the regulations applied to dietary supplements.


Q: Are there different strengths or versions of Simicol?

A: Yes, the active ingredient simethicone is available in multiple forms, including oral drops, chewable tablets, and swallowable capsules. These different forms are manufactured in various strengths to accommodate the recommended dosing ranges for adults and children.


Q: Is Simicol a controlled substance?

A: No, Simicol is not classified as a controlled substance according to regulatory documentation. The active ingredient, simethicone, has no scheduling under the Drug Enforcement Administration (DEA) guidelines.


Q: Does Simicol cause changes in sleep patterns?

A: Simicol is designed to work locally in the digestive tract and is not absorbed into the central nervous system. As a result, changes in sleep patterns or the onset of drowsiness are not expected or officially reported for the single-ingredient product.


Q: What are the signs that Simicol is not working?

A: The primary sign that the medication may not be working is if the physical symptoms of gas, bloating, and fullness do not improve. Official guidelines suggest consultation with a healthcare professional if symptoms persist or recur after a short course of use, typically 10 to 14 days.


Q: Is the tiredness I feel from Simicol a serious side effect?

A: Tiredness or fatigue is not listed in the official regulatory documentation as an adverse reaction to Simicol. Because the medication is not systemically absorbed, side effects affecting the whole body, such as tiredness, are not expected.


Q: What is the risk of having an allergic reaction to Simicol?

A: Allergic reactions, or hypersensitivity, are listed in regulatory warnings. These serious reactions, which include severe swelling of the face or throat, are considered rare (uncommon or frequency not known). Official product information notes that any sign of a serious allergic reaction is a medical emergency that requires immediate professional attention.


Q: Can Simicol be used to treat other conditions not listed on the label?

A: Simicol is approved only for its labeled use: the relief of pressure, bloating, and fullness commonly referred to as gas. The official uses for this medication are strictly limited to those conditions listed on the product label.


Q: Are there any mandatory tests required before starting Simicol?

A: Official regulatory labeling for Simicol does not mandate that any specific medical tests or laboratory work be completed before a person starts taking the medication.


Q: Is it possible for Simicol to cause mood changes?

A: Because Simicol is not systemically absorbed and does not act on the central nervous system, mood changes are not expected side effects and are not officially reported for the single-ingredient product.


Q: How does Simicol affect daily activities like driving?

A: Since the medicine is not systemically absorbed and does not affect the central nervous system, it does not cause side effects such as drowsiness or dizziness. Official information indicates that Simicol is unlikely to impair a person's ability to drive or operate machinery.


Q: What are the common misunderstandings about what Simicol is supposed to do?

A: The official drug facts clarify that Simicol is a physical agent, also known as an anti-foaming agent. Its purpose is to physically break down existing gas bubbles to aid their passage, rather than affecting the body's systemic processes or reducing the actual production of gas.


Q: What does 'contraindication' mean regarding Simicol?

A: A contraindication is an official term used in medicine that means the medication must not be used in specific circumstances due to the high risk of harm. For Simicol, official regulatory labeling lists the primary contraindications as a known allergy to the ingredients or a suspected or confirmed intestinal obstruction.


Q: If I have a medical condition not related to the one Simicol treats, can I still take it?

A: Because the medication is not systemically absorbed, it is not expected to interfere with the function of organs like the liver or kidneys. Regulatory information indicates that Simicol generally has a favorable profile for use with other stable health conditions, however, it is important to review the full list of contraindications to ensure none apply.


Q: What is the purpose of the boxed warning on Simicol's label?

A: The FDA label for the single-ingredient Simicol product does not contain a Boxed Warning. This specific regulatory warning is reserved for medications that carry a significant risk of serious or life-threatening adverse effects, which is not the classification of Simicol.


Q: Does Simicol impact fertility?

A: Due to its non-systemic absorption and lack of metabolism within the body, Simicol is not expected to impact fertility. No effects on reproductive function are reported in official regulatory documentation.


Q: What is the difference between an expected side effect and a serious one for Simicol?

A: Mild side effects for Simicol are generally local reactions, such as mild nausea or diarrhea. Serious side effects, on the other hand, are rare immune reactions like severe swelling of the face or throat, which are listed in the warnings as needing immediate medical attention.


Q: Why do official sources list so many potential side effects for Simicol?

A: Official regulatory agencies require comprehensive safety transparency and mandate the listing of all adverse events that were reported during clinical trials. This standard means that potential effects are listed regardless of whether their frequency is common or simply unknown, to inform the public.


Q: Is Simicol a new medication or has it been available for a while?

A: The active ingredient in Simicol, simethicone, is a long-established medication. Official records indicate that this compound has been in use since the 1940s and received its initial FDA approval in 1952.

How should Simicol be stored and disposed of?

Official Storage and Disposal Requirements

Simicol (Simethicone) must be stored strictly according to the conditions defined by regulatory documents to maintain its stability and effectiveness.

Storage & Handling Requirement Official Regulatory Statement
Temperature Store at controlled room temperature between 20 C and 25 C (68 F and 77 F), with temporary excursions permitted up to 30 C (86 F).
Protection The product must be protected from light, excessive heat, and moisture. Liquid forms must not be frozen as this can compromise physical stability.
Container Keep the medicine in its original container, tightly closed. Liquid products often require a light-resistant container.
Child Safety All forms of Simicol must be kept out of the sight and reach of children.
Disposal Disposal should utilize a drug take-back program when available. Otherwise, mix the product with an undesirable substance (like coffee grounds) in a sealed container before discarding in household trash. Do not flush the medicine down the toilet or sink.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Simicol found in:

A-Z Index: